SparingVision Email Formats
Biotechnology Research • 
Paris, Île-de-France, France • 21-50 Employees
SparingVision Email Formats
SparingVision uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@sparingvision.com), used 60.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@sparingvision.com | 60.5% |
{first name}.{last name} | john.doe@sparingvision.com | 30.2% |
{first initial}.{second initial}{last name} | j.odoe@sparingvision.com | 4.7% |
{first initial} | j@sparingvision.com | 4.7% |
Key Contacts at SparingVision
Pierre Axel Vinot
Director, Cmc Portfolio Management
Alexis Le Chevallier
Fp&A Director
Anne-Sophie Gautron
Director Translational Sciences
Fabien Dorange
Director Analytical Sciences
Jérôme Maes
Director, Global Project Lead
Gaelle Fanon
Quality Assurance Director
Laure Blouin
Director Clinical Science And Medical Communications
Prudence Hiscock Dischamp
Senior Legal Director
Lucile Bauché
Associate Director, Logistics
Nelle Messeca
Associate Director, Clinical Projects
Company overview
| Headquarters | 5-7, Avenue Percier, Paris, Île-de-France 75008, FR |
| Phone number | +3301434620 |
| Website | |
| SIC | 873 |
| Founded | 2016 |
| Employees | 21-50 |
| Socials |
About SparingVision
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
SparingVision has 21 employees across 9 departments.
Departments
Number of employees
SparingVision Tech Stack
Discover the technologies and tools that power SparingVision's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Video players
JavaScript libraries
Maps
UI frameworks
JavaScript libraries
JavaScript libraries
Web servers
Font scripts
JavaScript libraries
Denmark
Spain
Israel
Frequently asked questions
4.8
40,000 users
